CD8A and vitiligo: Similarly, a narrowed TCR diversity in peripheral CD8+ cells of alemtuzumab-treated RRMS patients has been recently confirmed by a HTS study (94); these patients were characterized for the presence of highly active CD8+ cells in peripheral blood and infiltrating derma and developed vitiligo 14, 18 and 52 months after starting the treatment, therefore suggesting that the kinetics of B cells reconstitution and narrowing of the TCR repertoire might be involved in the development of secondary autoimmunity observed following alemtuzumab treatment (93, 94).